Skip to content

Effects of consumption of the test food on swelling in healthy Japanese

Effects of consumption of the test food on swelling in healthy Japanese: a randomized, placebo-controlled, double-blind, crossover comparison study - Effects of consumption of the test food on swelling in healthy Japanese

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000059140
Enrollment
40
Registered
2026-04-30
Start date
2025-09-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese

Interventions

&lt
Duration&gt
Single administration (two periods) &lt
Test 1: Active food Test 2: Placebo food Lunch on each test day: Prescribed food &lt
Intervention sequence&gt
*Test 1 followed by Test 2. *The washout period will be two weeks. &lt
*Consume one capsule of the active food or placebo food with water after completing the morning measurements in each test of this study. *The prescribed meal will be consumed 2 hours after the start
Test 1: Placebo food Test 2: Active food Lunch on each test day: Prescribed food &lt

Sponsors

Fujicco Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Japanese 2. Men or women 3. Individuals aged between 20 and 64 4. Healthy individuals 5. Individuals who are concerned about lower leg swelling 6. Individuals whose BMI is >= 18.5 kg/m2 and < 30.0 kg/m2 at screening 7. Individuals with a large diurnal variation in lower leg volume (swelling) at screening 8. Individuals whose systolic blood pressure is < 130 mmHg and diastolic blood pressure is < 90 mmHg at screening 9. Individuals with no abnormalities in kidney function as determined by urinalysis at screening

Exclusion criteria

Exclusion criteria: 1. Individuals who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, or myocardial infarction 2. Individuals who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Individuals who are taking "Foods for Specified Health Uses" or "Foods with Functional Claims" 5. Individuals who are taking or using medicines (including herbal medicines) or supplements 6. Individuals who are allergic to medicines or foods related to the test product 7. Individuals with drinking habits exceeding moderate consumption 8. Individuals whose lifestyles are irregular due to working a late-night shift or others 9. Individuals who are undergoing exercise or alimentary therapy under medical supervision 10. Individuals who are pregnant, lactating, or planning to become pregnant during this study 11. Individuals who have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate in another study during this study 12. Individuals who are judged as ineligible to participate in this study by the physician

Design outcomes

Primary

MeasureTime frame
1. The measured value of swelling volume (evening lower leg volume minus morning lower leg volume)

Secondary

MeasureTime frame
1. The measured values of the lower leg volume in the morning and evening 2. The measured values of Visual Analogue Scale (VAS) for "I feel swelling face (cheeks or face line)," "I feel swelling around eyes," "I feel swelling calves," "I feel swelling the ankle (such as my socks feeling tight)," "I feel my complexion looks poor," and "I feel dark circles under my eyes" (Measurements include values in the morning, evening, and the following morning, as well as the difference between evening and morning values [evening minus morning], and between following morning and morning values [following morning minus morning])

Countries

Japan

Contacts

Public ContactNaoko Suzuki

ORTHOMEDICO Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026